RxDoctor Payments Data

Angela Singley, APRN

Nurse Practitioner · Corbin, KYNPI 1487649950

Payments from drug & device makers

$2,023in general payments, 2019–2025

Across 84 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$393
  • AstraZeneca$277
  • GSK$264
  • Genentech USA, Inc.$189
  • CSL Behring$161
  • Neurocrine Biosciences, Inc.$139
  • plus $601 from 11 others

What the payments were for

  • Food & beverage$1,91995%
  • Education$1045%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,023 in reported general payments places this provider in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$119,400
Medicare patients
51
Services billed
3,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5015$48,625
XolairOmalizumab12$32,666
Breo ElliptaFluticasone/Vilanterol17$9,159
Advair HfaFluticasone Propion/Salmeterol24$8,629
Epinephrine20$4,678
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,010
Albuterol Sulfate HfaAlbuterol Sulfate23$1,045
Ventolin HfaAlbuterol Sulfate11$734
Fluticasone Propionate75$686
Azelastine Hcl23$428
Montelukast Sodium77$332
Famotidine42$234
Levocetirizine Dihydrochloride42$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$161$48,62515 claims
GSKBreo Ellipta$264$9,15917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →